Limits of AI and Human Creativity

Dr. Omri Amirav-Drory is a General Partner at NFX whose mission in life is to end involuntary death. Omri has backed companies like Mammoth Biosciences, Immunai, and Centivax, and has earned a reputation as one of the most respected seed investors in tech-enabled life sciences and longevity. He previously founded Genome Compiler and sold it to Twist Bioscience, which is now worth $2.5 billion. We’ll talk about why longevity research could solve America's biggest economic problems, Omri’s 4 step ABCD plan for beating death, and why AI alone won’t solve aging.